IMA - Ikena Oncology, Inc.

5.81
-0.190   -3.270%

Share volume: 30,083
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$6.00
-0.19
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 21%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.53%
1 Month
3.20%
3 Months
-17.82%
6 Months
-20.30%
1 Year
388.24%
2 Year
346.92%
Key data
Stock price
$5.81
P/E Ratio 
N/A
DAY RANGE
$5.69 - $5.93
EPS 
-$6.31
52 WEEK RANGE
$1.04 - $18.00
52 WEEK CHANGE
$380.17
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
0.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,808,325
AVERAGE 30 VOLUME 
$958,620
Company detail
CEO: Mark Manfredi
Region: US
Website: ikenaoncology.com
Employees: 70
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Ikena Oncology, Inc. focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.

Recent news